Drug intelligence / Profile preview

AC058

Development stage: Unknown
Lead developer: OMJ Pharmaceuticals
Administration: Oral

Overview

AC058 is an oncology drug under development by ACEA Biosciences. As of November 2015, it was entering Phase I clinical trials in the United States. The specific mechanism of action for AC058 has not been disclosed in the available information.

Targets

BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on AC058.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AC058.

Explore the full profile